282 related articles for article (PubMed ID: 36918220)
1. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.
Rizvi N; Ademuyiwa FO; Cao ZA; Chen HX; Ferris RL; Goldberg SB; Hellmann MD; Mehra R; Rhee I; Park JC; Kluger H; Tawbi H; Sullivan RJ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918220
[TBL] [Abstract][Full Text] [Related]
2. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
Atkins MB; Ascierto PA; Feltquate D; Gulley JL; Johnson DB; Khushalani NI; Sosman J; Yap TA; Kluger H; Sullivan RJ; Tawbi H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918225
[TBL] [Abstract][Full Text] [Related]
3. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.
Kluger H; Barrett JC; Gainor JF; Hamid O; Hurwitz M; LaVallee T; Moss RA; Zappasodi R; Sullivan RJ; Tawbi H; Sharon E
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918224
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development.
Kluger HM; Tawbi H; Feltquate D; LaVallee T; Rizvi NA; Sharon E; Sosman J; Sullivan RJ
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37487665
[TBL] [Abstract][Full Text] [Related]
6. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Naidoo J; Murphy C; Atkins MB; Brahmer JR; Champiat S; Feltquate D; Krug LM; Moslehi J; Pietanza MC; Riemer J; Robert C; Sharon E; Suarez-Almazor ME; Suresh K; Turner M; Weber J; Cappelli LC
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001909
[TBL] [Abstract][Full Text] [Related]
7. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.
Zouein J; Haddad FG; Eid R; Kourie HR
Immunotherapy; 2022 Feb; 14(2):155-167. PubMed ID: 34865502
[TBL] [Abstract][Full Text] [Related]
8. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy.
Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
[TBL] [Abstract][Full Text] [Related]
9. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
Wang Z; Wang Y; Gao P; Ding J
Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
[TBL] [Abstract][Full Text] [Related]
11. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer.
Kelly RJ; Bever K; Chao J; Ciombor KK; Eng C; Fakih M; Goyal L; Hubbard J; Iyer R; Kemberling HT; Krishnamurthi S; Ku G; Mordecai MM; Morris VK; Paulson AS; Peterson V; Shah MA; Le DT
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286304
[TBL] [Abstract][Full Text] [Related]
12. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
Pavlick AC; Ariyan CE; Buchbinder EI; Davar D; Gibney GT; Hamid O; Hieken TJ; Izar B; Johnson DB; Kulkarni RP; Luke JJ; Mitchell TC; Mooradian MJ; Rubin KM; Salama AK; Shirai K; Taube JM; Tawbi HA; Tolley JK; Valdueza C; Weiss SA; Wong MK; Sullivan RJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852736
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
15. Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC).
Atkins MB; Abu-Sbeih H; Ascierto PA; Bishop MR; Chen DS; Dhodapkar M; Emens LA; Ernstoff MS; Ferris RL; Greten TF; Gulley JL; Herbst RS; Humphrey RW; Larkin J; Margolin KA; Mazzarella L; Ramalingam SS; Regan MM; Rini BI; Sznol M
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36175037
[TBL] [Abstract][Full Text] [Related]
16. Failure of Immunotherapy-The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer.
Błach J; Wojas-Krawczyk K; Nicoś M; Krawczyk P
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445735
[TBL] [Abstract][Full Text] [Related]
17. The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma.
Yuan H; Liu J; Zhang J
Molecules; 2021 Mar; 26(5):. PubMed ID: 33807509
[TBL] [Abstract][Full Text] [Related]
18. Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Pala L; Sala I; Oriecuia C; De Pas T; Queirolo P; Specchia C; Cocorocchio E; Ferrucci P; Patanè D; Saponara M; Pennacchioli E; Coppola S; Viale G; Giaccone G; Gelber RD; Bagnardi V; Conforti F
JAMA Netw Open; 2022 Aug; 5(8):e2226252. PubMed ID: 35972744
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
Front Immunol; 2021; 12():651086. PubMed ID: 34248939
[TBL] [Abstract][Full Text] [Related]
20. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.
Govindan R; Aggarwal C; Antonia SJ; Davies M; Dubinett SM; Ferris A; Forde PM; Garon EB; Goldberg SB; Hassan R; Hellmann MD; Hirsch FR; Johnson ML; Malik S; Morgensztern D; Neal JW; Patel JD; Rimm DL; Sagorsky S; Schwartz LH; Sepesi B; Herbst RS
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
